• Mashup Score: 0
    Relay Therapeutics Pauses Lirafugratinib Rare Cancer Plans Due to IRA - 7 month(s) ago

    The biotech will pause its lirafugratinib program for a rare bile duct cancer to target a larger FGFR2-altered solid tumors population, citing the Inflation Reduction Act as a driving decision factor.

    Source: www.biospace.com
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of MarkYarchoan
      MarkYarchoan

      Biotechs are delaying approvals of life-saving drugs for rare cancers to avoid starting the 9y clock on Medicare negot. RLY4008 is highly effective for FGFR2+ #cholangiocarcinoma but company waiting to file in a larger indication: https://t.co/GKgJM1xSRs

  • Mashup Score: 0
    Independent of Primary Sclerosing Cholangitis and Cirrhosis, Early Adulthood Obesity Is Associated with Cholangiocarcinoma - 7 month(s) ago

    AbstractBackground:. It is estimated that 6% to 20% of all cholangiocarcinoma (CCA) diagnoses are explained by primary sclerosing cholangitis (PSC), but the underlying risk factors in the absence of PSC are unclear. We examined associations of different risk factors with intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC) in the United States.Methods:. We conducted a case–control study of 121 patients with ECC and 308 patients with ICC treated at MD Anderson Cancer Center between May 2014 and March 2020, compared with 1,061 healthy controls. Multivariable logistic regression analysis was applied to estimate the adjusted OR (AOR) and 95% confidence interval (CI) for each risk factor.Results:. Being Asian, diabetes mellitus, family history of cancer, and gallbladder stones were associated with higher odds of developing ICC and ECC. Each 1-unit increase in body mass index in early adulthood (ages 20–40 years) was associated with a decrease in age at diagnosis o

    Source: aacrjournals.org
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CEBP_AACR
      CEBP_AACR

      Hatia, Eluri et al study the associations of different risk factors with #cholangiocarcinoma in the US and find that early adulthood onset of #obesity was significantly associated and may predict early diagnosis at younger age. https://t.co/n9BybvjVpF https://t.co/sHbjOm0sNr

  • Mashup Score: 3
    Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy - 7 month(s) ago

    Objective Cytotoxic agents are the cornerstone of treatment for patients with advanced intrahepatic cholangiocarcinoma (iCCA), despite heterogeneous benefit. We hypothesised that the pretreatment molecular profiles of diagnostic biopsies can predict patient benefit from chemotherapy and define molecular bases of innate chemoresistance. Design We identified a cohort of advanced iCCA patients with comparable baseline characteristics who diverged as extreme outliers on chemotherapy (survival <6 m in rapid progressors, RP; survival >23 m in long survivors, LS). Diagnostic biopsies were characterised by digital pathology, then subjected to whole-transcriptome profiling of bulk and geospatially macrodissected tissue regions. Spatial transcriptomics of tumour-infiltrating myeloid cells was performed using targeted digital spatial profiling (GeoMx). Transcriptome signatures were evaluated in multiple cohorts of resected cancers. Signatures were also characterised using in vitro cell lines, in

    Source: gut.bmj.com
    Categories: Gastroenterology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of Gut_BMJ
      Gut_BMJ

      RT @nigeljamieson: Check out 🔻🔻 #cholangiocarcinoma Paper from @chiarabraconi @ColmJJORourke https://t.co/5XjyN61SEY Well done @LabSpat…

Load More